Drug Profile

Research programme: sickle cell anaemia therapeutics - San Rocco Therapeutics

Alternative Names: Trichosic

Latest Information Update: 10 May 2021

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Errant Gene Therapeutics
Developer San Rocco Therapeutics
Class Antibacterials; Antifungals; Antineoplastics; Skin disorder therapies; Small molecules
Mechanism of Action Histone deacetylase inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

05 May 2021 Errant Gene Therapeutics is now called San Rocco Therapeutics
28 Aug 2020 No recent reports of development identified for preclinical development in Sickle-cell-anaemia in USA
15 Jul 2016 Preclinical trials in Sickle cell anaemia in USA (unspecified route)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com